Skip to main content
Premium Trial:

Request an Annual Quote

John Rawling, John Morrison, Donald Picker

Premium
Benitec announced this week that it has appointed John Rawling as co-company secretary and accountant.
 
Rawling is a chartered accountant who also is currently secretary and CFO of EQiTX, an Australian biotech firm currently undergoing a restructuring. Benitec’s current CEO, Sue Macleman, was formerly the CEO of EQiTX.
 
Benitec also said that John Morrison has been named business development and licensing manager for the company. He was most recently a business development consultant at BioComm Services, an Australian technology management and commercial development firm.
 

 
Tapestry Pharmaceuticals said last month that it has named Donald Picker as its president.
 
Picker had previously been senior vice president of research and development at antisense drug firm Genta, where he helped develop the company’s now-failed cancer drug Genasense.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.